摘要
目的探讨低分子肝素治疗对改善老年重症肺炎预后的临床价值。方法选取我院收治的80例重症肺炎患者,随机分为观察组(n=40,常规治疗+低分子肝素治疗)和参考组(n=40,常规治疗)。比较两组治疗效果。结果治疗后,两组的APPACHEⅡ及PSI评分、CRP、PCT、TNF-α、Pa O2水平及OI均显著改善,且观察组的APPACHEⅡ及PSI评分、CRP、PCT、TNF-α、Pa O2、Pa CO2水平及OI明显优于参考组(P<0.05)。观察组的治疗总有效率明显高于参考组(P<0.05)。结论常规治疗基础上辅助抗凝治疗有助于改善老年重症肺炎炎症反应、缺氧状态,近期效果确切。
Objective To investigate the clinical value of low molecular weight heparin in improving the prognosis of elderly patients with severe pneumonia. Methods Eighty patients with severe pneumonia admitted in our hospital were selected and randomly divided into observation group(n=40, conventional treatment+low molecular weight heparin treatment)and reference group(n=40, conventional treatment). The treatment effects of the two groups were compared. Results After treatment, the scores of APPACHE Ⅱ and PSI, CRP, PCT, TNF-α and Pa O2 levels, OI in the two groups significantly improved, and the scores of APPACHEⅡ and PSI, CRP, PCT, TNF-α, Pa O2 and Pa CO2 levels, OI of the observation group were significantly better than those of the reference group(P〈0.05). The total effective rate of treatment in the observation group was significantly higher than that in the reference group(P〈0.05). Conclusion The adjuvant anticoagulation therapy on the basis of routine treatment is helpful to improve the inflammatory reaction and hypoxia of severe pneumonia in elderly patients, which has exact effect.
作者
孙玉冰
SUN Yu-bing(No.1 Internal Medicine Department, the People's Hospital of Ansai District, Yan'an 717400, China)
出处
《临床医学研究与实践》
2018年第19期28-29,共2页
Clinical Research and Practice
关键词
低分子肝素
老年重症肺炎
APPACHEⅡ评分
炎症因子
low molecular weight heparin
elderly severe pneumonia
scores of APPACHEⅡ
Inflammatory factors